Ask AI
H.R. 7032

Increasing Transparency in Generic Drug Applications Act of 2022

Increasing Transparency in Generic Drug Applications Act of 2022

This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

Referred to the Subcommittee on Health.

Rep. Kuster, Ann M. [D-NH-2](D-NH)Sponsor
1 cosponsor1 D
1cosponsors1committees4actions2related bills4subjects
  1. Committee

    Referred to the Subcommittee on Health.

    Health Subcommittee
  2. IntroReferralH11100

    Referred to the House Committee on Energy and Commerce.

    Energy and Commerce Committee
  3. IntroReferralIntro-H

    Introduced in House

  4. IntroReferral1000

    Introduced in House

Increasing Transparency in Generic Drug Applications Act of 2022 — Informed